MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2019 International Congress

    Supportive treatments for Ataxia, a Randomized Control Trial

    MIA. Arain (Jamshoro, Pakistan)

    Objective: The objective of this study is to evaluate the effectiveness of supporting treatments that improve awareness and the quality of patient life and counsel…
  • 2019 International Congress

    A homozygous pentanucleotide repeat expansion in cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS)

    M. Gisatulin, V. Dobricic, Y. Hellenbroich, V. Tadic, A. Münchau, C. Zühlke, M. Bahlo, P. Lockhart, K. Lohmann, C. Helmchen, N. Brüggemann (Lübeck, Germany)

    Objective: To identify the genetic cause in patients with CANVAS recruited at the University Hospital of Schleswig-Holstein, Campus Lübeck. Background: CANVAS is a late-onset neurological…
  • 2019 International Congress

    Epidemiological study of multiple system atrophy: data from HoRC-MSA Project 2014-2019

    M. Matsushima, I. Yabe, K. Sakushima, I. Iwata, Y. Kanatani, N. Nishimoto, T. Matsuoka, T. Katayama, H. Uesugi, K. Sako, A. Takei, A. Tamakoshi, S. Shimohama, N. Sato, S. Kikuchi, H. Sasaki (Sapporo, Japan)

    Objective: To investigate epidemiological aspects of multiple system atrophy (MSA) in Hokkaido, Japan from the data of the Hokkaido Rare-disease Consortium for MSA (HoRC-MSA). Background:…
  • 2019 International Congress

    Clinico-genetic correlation in 102 Spinocerebellar Ataxia Type 12 (SCA 12) patients

    AK. Srivastava, A. Takkar, V. Goyal, F. Mohammad, R. Rajan, A. Garg (New Delhi, India)

    Objective: To report the phenotype among the largest number of genotypically confirmed SCA 12 patients. Background: SCA12 is an autosomal dominant cerebellar ataxia (ADCA) caused…
  • 2019 International Congress

    Acute hemichorea in patient of uncontrolled type 2 diabetes mellitus; a case report with characteristic imaging

    M. Salem, A. Helmy, E. Abdeldayem, A. Shalash (Cairo, Egypt)

    Objective: chorea is a rare complication of uncontrolled type 2 diabetes . we report a case of hyperglycemia, due to uncontrolled type 2 diabetes, presented…
  • 2019 International Congress

    A retrospective analysis of clinical and electrophysiological characteristics of patients with myoclonus

    A. Gunduz, M. E. Kızıltan, H. Ser, N. Yeni, C. Ozkara, V. Demirbilek, C. Yalçınkaya, G. Kızıltan (Istanbul, Turkey)

    Objective: We aimed to evaluate the clinical characteristics of patients with myoclonus and to identify the possible etiologies in different types of myoclonus based on…
  • 2019 International Congress

    Ferroptosis, a recently identified cell death, as a therapeutic target for Parkinson’s disease.

    H. Bouchaoui, L. Mahoney-Sanchez, A. Jonneaux, F. Gouel, M. Dutheil, JC. Devedjian, G. Garçon, D. Devos (Lille, France)

    Objective: We aim to determine in a cell model neuroprotective effects of targeting lipoxygenases (LOXs), central players in Ferroptosis, a novel regulated iron-dependent cell death…
  • 2019 International Congress

    Evolution of anti-parkinsonian drug prescribing patterns in Parkinson’s disease

    S. Neo, A. Wong, HL. Ng, W. Li, KY. Tay, WL. Au, L. Tan (Singapore, Singapore)

    Objective: To compare Parkinson’s disease (PD) treatment practices by movement disorder (MD) specialists across a decade, and to determine the factors that influence drug choice…
  • 2019 International Congress

    Progression of neuropsychiatric symptoms in Parkinson’s disease

    J. Dlay, G. Duncan, T. Khoo, C. Williams-Gray, D. Breen, R. Barker, D. Burn, R. Lawson, A. Yarnall (Newcastle Upon Tyne, United Kingdom)

    Objective: To determine the progression of neuropsychiatric symptoms (NPS) in Parkinson’s disease (PD) and their associations with quality of life (QoL) and motor problems. Background:…
  • 2019 International Congress

    Diagnosis and management strategies used in series of Parkinson’s disease patients who experienced subthalamic nucleus deep brain stimulation induced mood elevation

    L. Spiegel, J. Weinstein, J. Ostrem, A. Seritan (San Francisco, CA, USA)

    Objective: To describe the diagnosis and management of deep brain stimulation-induced elevated mood states. Background: Deep brain stimulation (DBS) is an FDA-approved surgical treatment option…
  • « Previous Page
  • 1
  • …
  • 200
  • 201
  • 202
  • 203
  • 204
  • …
  • 217
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Welcome to the MDS Abstracts Site
  • Effect of marijuana on Essential Tremor: A case report
  • Advanced Search
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley